Back to top
more

Elevance Health, Inc. (ELV)

(Delayed Data from NYSE)

$417.77 USD

417.77
2,046,399

-0.09 (-0.02%)

Updated Nov 5, 2024 04:00 PM ET

After-Market: $417.83 +0.06 (0.01%) 5:14 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

5-Strong Sell of 5         5

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value B Growth F Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 38% (154 out of 250)

Industry: Medical Services

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Elevance Health (ELV) Gains But Lags Market: What You Should Know

by Zacks Equity Research

Elevance Health (ELV) closed at $449.26 in the latest trading session, marking a +0.11% move from the prior day.

Here's Why Investors are Retaining Elevance (ELV) Stock Now

by Zacks Equity Research

Elevance's (ELV) focus on expanding the capabilities of the Carelon platform is likely to position the company for long-term growth.

Elevance Health (ELV) Gains As Market Dips: What You Should Know

by Zacks Equity Research

In the latest trading session, Elevance Health (ELV) closed at $450.15, marking a +1.76% move from the previous day.

Elevance Health (ELV) Stock Moves 0.38%: What You Should Know

by Zacks Equity Research

Elevance Health (ELV) closed the most recent trading day at $459.57, moving +0.38% from the previous trading session.

Medtronic's (MDT) Inceptiv Spinal Cord Stimulator Gets CE Mark

by Zacks Equity Research

Medtronic's (MDT) Inceptiv SCS System is the first Medtronic SCS device to offer a closed-loop feature that senses each person's unique biological signals.

BrainsWay (BWAY) Expands Foothold in Taiwan With Deep TMS

by Zacks Equity Research

The collaboration between BrainsWay (BWAY) and Unison Healthcare Group signifies a coordinated effort to enhance access and awareness of Deep TMS in Taiwan.

LabCorp (LH) Suffers From Lower COVID Test Sales, Macro Woes

by Zacks Equity Research

Labcorp's (LH) Early Development Research Laboratories business continues to be constrained by NHP-related supply-chain issues.

Charles River (CRL) Collaborates With Fondazione Telethon

by Zacks Equity Research

Charles River (CRL) is excited about Fondazione Telethon's collaboration to produce HQ plasmid DNA for the lentivirus used in ex vivo gene therapy developed by Fondazione Telethon.

Elevance Health (ELV) Stock Moves -0.84%: What You Should Know

by Zacks Equity Research

In the latest trading session, Elevance Health (ELV) closed at $456, marking a -0.84% move from the previous day.

Here's Why You Should Retain Hologic (HOLX) Stock for Now

by Zacks Equity Research

Investors are optimistic about Hologic (HOLX) on the expanded global installed base of more than 3,250 Panthers instruments, representing the catalyst for sustained growth.

Veeva Systems (VEEV) to Support Civica Rx Quality Control

by Zacks Equity Research

Veeva Systems' (VEEV) Vault LIMS will streamline internal testing and manufacturing while promoting lead time adherence.

Thermo Fisher (TMO) Launches New Chromosomal Microarray

by Zacks Equity Research

Thermo Fisher's (TMO) CytoScan HD Accel array can save labs weeks or even months by accelerating the time it takes to get findings from cytogenetic research.

Here's Why Investors Should Retain STERIS (STE) Stock for Now

by Zacks Equity Research

Investors are optimistic about STERIS' (STE) successful integration of the recently-acquired business and raised guidance.

Here's Why You Should Invest in Align Technology (ALGN) Now

by Zacks Equity Research

Investors are optimistic about Align Technology (ALGN), led by Invisalign portfolio expansion and raised guidance.

Here's Why You Should Invest in Penumbra (PEN) Stock for Now

by Zacks Equity Research

Investors are upbeat about Penumbra (PEN) on Strong uptake following the launch of Lightning Flash, which accelerated top-line growth.

Why Is Elevance Health (ELV) Down 3.4% Since Last Earnings Report?

by Zacks Equity Research

Elevance Health (ELV) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

The Zacks Analyst Blog Highlights Accenture, Elevance Health, Analog Devices, Monster Beverage and West Pharmaceutical Services

by Zacks Equity Research

Accenture, Elevance Health, Analog Devices, Monster Beverage and West Pharmaceutical Services are part of the Zacks top Analyst Blog.

Sheraz Mian headshot

Top Research Reports for Accenture, Elevance Health & Analog Devices

by Sheraz Mian

Today's Research Daily features new research reports on 16 major stocks, including Accenture plc (ACN), Elevance Health, Inc. (ELV) and Analog Devices, Inc. (ADI).

Alcon (ALC) Q2 Earnings Surpass Estimates, Margins Increase

by Zacks Equity Research

Alcon (ALC) delivers better-than-expected earnings and revenues in the second quarter of 2023.

Here's Why Elevance Health (ELV) is a Strong Value Stock

by Zacks Equity Research

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Asensus Surgical (ASXC) Q2 Loss Widens, Revenues In Line

by Zacks Equity Research

Asensus Surgical (ASXC) reports a significant increase in total surgical procedures completed utilizing the Senhance System.

National Vision (EYE) Q2 Earnings Top Estimates, Margins Down

by Zacks Equity Research

National Vision's (EYE) second-quarter 2023 performance highlights positive comparable store sales growth, retention and recruitment trends.

Here's How Much You'd Have If You Invested $1000 in Elevance Health a Decade Ago

by Zacks Equity Research

Holding on to popular or trending stocks for the long-term can make your portfolio a winner.

Charles River (CRL) Q2 Earnings Top, 2023 View Narrowed

by Zacks Equity Research

Charles River (CRL) registers robust growth in small research models, research model services and the Safety Assessment business.

Insulet (PODD) Q2 Earnings Beat, Sales Growth View Raised

by Zacks Equity Research

Insulet's (PODD) Omnipod 5 gains market share in the second quarter within the diabetes technology market as the only FDA-approved fully disposable, pod-based automated insulin delivery system.